<DOC>
	<DOCNO>NCT00742300</DOCNO>
	<brief_summary>While glucocorticoid immunosuppressant ameliorate manifestation autoimmune disease many patient , current therapy insufficient control disease subset patient , clinical prognosis remain poor due development vital organ failure , cumulative drug toxicity increase risk cardiovascular disease malignancy . Immunoablative chemotherapy follow autologous hematopoietic stem cell transplantation ( ASCT ) recently emerge promising experimental therapy severely affect patient , provide potential achieve treatment-free , long-term remission . The rationale apply ASCT autoimmune disease hope immunoablation could eliminate inflammation-driving pathogenic cell immune system , regeneration patient ' immune system hematopoietic precursor could re-establish immunological tolerance .</brief_summary>
	<brief_title>Autologous Hematopoietic Stem Cell Transplantation Refractory Autoimmune Diseases</brief_title>
	<detailed_description />
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Autoimmune disease Active disease inadequate response standard protocol ( glucocorticoid least two different regimen immunosuppressive drug , intravenous cyclophosphamide 8001000mg/application ) Provision inform consent subject Active chronic infection Uncontrolled arrhythmia congestive heart failure ( ejection fraction 50 % determined echocardiogram ) Lung fibrosis ( transfer factor carbon monoxide [ TLCO ] &lt; 45 % ) renal insufficiency ( glomerular filtration rate 40 ml/min ) Pulmonary arterial hypertension ( &gt; 40mmHg ) History malignancy Women pregnant breastfeeding Use nonreliable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>ASCT</keyword>
	<keyword>Tolerance induction</keyword>
	<keyword>SLE</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Autoimmune disease</keyword>
</DOC>